Article
Oncology
Ghaith Abu-Zeinah, Spencer Krichevsky, Tatiana Cruz, Gabriela Hoberman, Diana Jaber, Niamh Savage, Claudia Sosner, Ellen K. Ritchie, Joseph M. Scandura, Richard T. Silver
Summary: The study suggests that treatment of PV with rIFN alpha can reduce the risk of myelofibrosis and mortality, especially in high-risk patients.
Article
Hematology
Olga K. Weinberg, Alexa Siddon, Yazan F. Madanat, Jeffrey Gagan, Daniel A. Arber, Paola Dal Cin, Damodaran Narayanan, Madhu M. Ouseph, Jason H. Kurzer, Robert P. Hasserjian
Summary: This study evaluated the clinicopathologic features and outcomes of AML and MDS patients with complex karyotype (CK). The presence of TP53 mutation, especially multihit TP53 mutation, in the context of CK, identified a homogeneously aggressive disease, irrespective of blast count or therapy-relatedness.
Article
Medicine, General & Internal
Anne Jacobsen, Mirianna Hobbs, Susanne Merkel, Anke Mittelstaedt, Franziska Czubayko, Christian Krautz, Georg F. Weber, Robert Gruetzmann, Maximilian Brunner
Summary: This study investigated the prognostic value of time from diagnosis to surgery in patients undergoing upfront surgery for primarily resectable pancreatic carcinoma. The results showed that a delay of surgery > 23 days after diagnosis does not affect overall or disease-free survival of patients with primary resectable PDAC. Age, lymph node metastasis, tumor differentiation, and resection status were identified as significant independent prognostic predictors.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Alessandra Iurlo, Francesca Palandri, Elena Maria Elli, Daniele Cattaneo, Cristina Bucelli, Mariarita Sciume, Donatella Vincelli, Filippo Brioschi, Giuseppe Auteri, Giorgio Alberto Croci, Silvana Guerneri, Giuseppe Isimbaldi, Elena Sabattini, Ivan Cortinovis, Anna Bossi, Vittorio Rosti, Bruno Martino, Luca Baldini, Umberto Gianelli
Summary: This study analyzed cytogenetic data of 395 primary myelofibrosis patients, finding a correlation between karyotype and disease progression, with abnormal karyotype patients having poorer survival outcomes.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Biophysics
Shohei Yamamoto, Motohiro Kato, Kenichiro Watanabe, Sae Ishimaru, Daisuke Hasegawa, Maiko Noguchi, Asahito Hama, Maho Sato, Takashi Koike, Fuminori Iwasaki, Hiroshi Yagasaki, Yoshiyuki Takahashi, Yoshiyuki Kosaka, Yoshiko Hashii, Akira Morimoto, Yoshiko Atsuta, Daiichiro Hasegawa, Nao Yoshida
Summary: Cytogenetic abnormalities are a significant risk factor for relapse after HSCT in pediatric MDS patients. The revised International Prognostic Scoring System classification could effectively predict the outcome based on cytogenetic characteristics, with very poor risk independently predicting worse outcomes after HSCT.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Silvia Ramos-Campoy, Anna Puiggros, Silvia Bea, Sandrine Bougeon, Maria Jose Larrayoz, Dolors Costa, Helen Parker, Gian Matteo Rigolin, Margarita Ortega, Maria Laura Blanco, Rosa Collado, Rocio Salgado, Tycho Baumann, Eva Gimeno, Carolina Moreno, Francesc Bosch, Xavier Calvo, Maria Jose Calasanz, Antonio Cuneo, Jonathan C. Strefford, Florence Nguyen-Khac, David Oscier, Claudia Haferlach, Jacqueline Schoumans, Blanca Espinet
Summary: This study compared the effectiveness of chromosome banding analysis (CBA) and genomic microarrays (GM) in risk stratification of CLL patients. The results showed moderate agreement between the two methods, but discordant classification in individual cases. Most discrepancies were technique-dependent and no significant correlation in the number of abnormalities was found when different filtering strategies were applied for GM. However, both CBA and GM showed similar predictive values for time to first treatment (TTFT) and overall survival. High complexity defined by both CBA and GM remained significant in the multivariate analysis for TTFT. Validation studies are needed to establish the prognostic value of genome complexity based on GM data in future prospective studies.
Review
Oncology
F. Nguyen-Khac, A. Bidet, A. Daudignon, M. Lafage-Pochitaloff, G. Ameye, C. Bilhou-Nabera, E. Chapiro, M. A. Collonge-Rame, W. Cuccuini, N. Douet-Guilbert, V Eclache, I Luquet, L. Michaux, N. Nadal, D. Penther, B. Quilichini, C. Terre, C. Lefebvre, M-B Troadec, L. Veronese
Summary: The complexity of karyotype has significant prognostic value in various malignancies, but there is no consensus on its definition and the prognostic impact varies among diseases. The GFCH has developed a practical document to aid cytogeneticists in assessing complex karyotypes in hematological disorders. Standardizing the evaluation of karyotype complexity and establishing consensus prognostic cut-offs for each disease is necessary.
Article
Oncology
Zengtuan Xiao, Mengzhe Zhang, Zuo Liu, Xiaofei Wang, Zhe Liu, Zhenfa Zhang
Summary: This study aimed to provide a standard for surgery in patients with primary endobronchial neoplasm. The optimal cut-off value for the distance between tumor and bronchial resection margin (DBTM) was determined to be 1.7 cm. Patients with DBTM = 1.7 cm should actively receive adjuvant therapy after surgery.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Xiangyang Yu, Feng Wang, Longjun Yang, Kai Ma, Xiaotong Guo, Lixu Wang, Longde Du, Xin Yu, Shengcheng Lin, Hua Xiao, Zhilin Sui, Lanjun Zhang, Zhentao Yu
Summary: In this study, nomograms were developed to predict disease-free survival (DFS) and overall survival (OS) for patients who underwent pneumonectomy for primary lung cancer. The nomograms showed good discrimination accuracy and clinical utility. They can assist in identifying high-risk patients and developing personalized treatment strategies to improve survival.
Article
Biophysics
Antonio M. Jimenez Jimenez, Marcos De Lima, Krishna Komanduri, Trent P. Wang, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Hassan Alkhateeb, Amer Assal, Ulrike Bacher, Frederic Baron, Minoo Battiwalla, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Michael Byrne, Jean-Yves Cahn, Mitchell Cairo, Paul Castillo, Edward Copelan, Zachariah DeFilipp, Miguel Angel Diaz Perez, Mahmoud Elsawy, Robert Peter Gale, Biju George, Michael R. Grunwald, Gerhard C. Hildebrandt, William J. Hogan, Christopher G. Kanakry, Ankit Kansagra, Mohamed A. Kharfan-Dabaja, Nandita Khera, Maxwell M. Krem, Aleksandr Lazaryan, Joseph Maakaron, Rodrigo Martino, Joseph McGuirk, Fotios Michelis, Giuseppe Milone, Asmita Mishra, Hemant S. Murthy, Alberto Mussetti, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Neil Palmisiano, Sagar Patel, Ayman Saad, Sachiko Seo, Akshay Sharma, Melhem Solh, Leo F. Verdonck, Baldeep Wirk, Jean A. Yared, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Wael Saber, Daniel Weisdorf
Summary: The study established an adapted European LeukemiaNet (aELN) risk classification to predict post-transplant outcomes in adult AML patients, finding that patients in the adverse risk group had the highest risk of relapse and inferior disease-free and overall survival, highlighting the need for novel approaches to mitigate relapse in this high-risk group.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Andrew T. Kuykendall, Libo Sun, John Mascarenhas, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Julia Wang, Qi Xia, Eugene Zhu, Faye Feller, Aleksandra Rizo, Jacqueline Bussolari, Ying Wan, Rami Komrokji
Summary: Treatment with imetelstat resulted in longer overall survival compared to BAT in closely matched patients with MF after JAK inhibitor failure, with a significantly lower risk of death. Further evaluation of imetelstat in this poor-prognosis patient population is warranted based on these promising results.
ANNALS OF HEMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Mingzhu Song, Tun Zhang, Dongdong Yang, Hao Xiao, Huiping Wang, Qianling Ye, Zhimin Zhai
Summary: This study retrospectively analyzed the clinical characteristics and chromosomal aberrations in 26 patients with secondary acute myeloid leukemia (S-AML). The results showed that about 62% of S-AML patients had chromosomal aberrations, and patients with abnormal karyotype had higher serum lactate dehydrogenase (LDH) levels. In addition, S-AML patients with chromosomal aberrations had shorter overall survival (OS). Therefore, chromosomal aberrations in S-AML patients can affect their prognosis.
Article
Oncology
Yu Liu, Ruyue Zheng, Yajun Liu, Lu Yang, Tao Li, Yafei Li, Zhongxing Jiang, Yanfang Liu, Chong Wang, Shujuan Wang
Summary: Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with improved outcomes through children-like regimens and novel agents; Factors affecting prognosis include age, white blood cell count, and genetic abnormalities; A prognostic model has been developed to predict overall survival in newly diagnosed ALL patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Kelly J. Norsworthy, Xin Gao, Chia-Wen Ko, E. Dianne Pulte, Jiaxi Zhou, Yutao Gong, Yuan Li Shen, Jonathon Vallejo, Thomas E. Gwise, Rajeshwari Sridhara, Albert B. Deisseroth, Ann T. Farrell, R. Angelo de Claro, Gideon M. Blumenthal, Richard Pazdur
Summary: The study explores the associations between response and survival outcomes in newly diagnosed acute myeloid leukemia (AML) patients undergoing intensive chemotherapy. The analysis reveals a moderate association between complete remission (CR) rate and overall survival (OS), and a strong association between event-free survival (EFS) and OS. However, the confidence intervals are wide, and the results became moderate when using alternative definitions for EFS. Patient-level analysis shows that CR responders have better OS compared to CRi or CRp responders and nonresponders.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Susan DeWolf, Martin S. Tallman, Jacob M. Rowe, Meira Yisraeli Salman
Summary: Although allogeneic hematopoietic cell transplantation (allo-HCT) is the main treatment for AML, some patients can achieve long-term remission without transplantation. Recent advances in our understanding of AML biology have changed the diagnosis, management, and treatment of AML, providing a new paradigm for patient care. This review aims to analyze the decision of whether to proceed with transplantation for patients with AML in first complete remission based on available evidence, focusing on factors affecting the biology and treatment of AML itself.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Alfredo Molteni, Marta Riva, Lorenza Borin, Massimo Bernardi, Anna Maria Pelizzari, Alessandra Freyrie, Matteo Della Porta, Michele Nichelatti, Emanuele Ravano, Giulia Quaresmini, Jacopo Mariotti, Domenica Caramazza, Marta Ubezio, Simona Guarco, Federica Gigli, Rosa Greco, Roberto Cairoli, Enrica Morra
Article
Hematology
Francesco Passamonti, Domenica Caramazza, Barbara Mora, Rosario Casalone, Margherita Maffioli
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
(2014)
Article
Hematology
Srdan Verstovsek, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, Tapan Kadia, Sherry Pierce, Elias Jabbour, Gautham Borthakur, Elisa Rumi, Ester Pungolino, Enrica Morra, Domenica Caramazza, Mario Cazzola, Francesco Passamonti
Article
Hematology
Francesco Passamonti, Margherita Maffioli, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Tiziano Barbui, Domenica Caramazza, Lisa Pieri, Elisa Rumi, Heinz Gisslinger, Laurent Knoops, Jean Jaques Kiladjian, Barbara Mora, Norbert Hollaender, Cristiana Pascutto, Claire Harrison, Mario Cazzola
Review
Hematology
Francesco Passamonti, Margherita Maffioli, Domenica Caramazza
CURRENT OPINION IN HEMATOLOGY
(2012)
Article
Oncology
Francesco Passamonti, Margherita Maffioli, Michele Merli, Andrea Ferrario, Domenica Caramazza
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2012)
Article
Oncology
Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, Geeta George, Kebede Begna, Susan Schwager, Daniel Van Dyke, Curtis Hanson, Wenting Wu, Animesh Pardanani, Francisco Cervantes, Francesco Passamonti, Ayalew Tefferi
JOURNAL OF CLINICAL ONCOLOGY
(2011)
Article
Oncology
Ayalew Tefferi, Rakhee Vaidya, Domenica Caramazza, Christy Finke, Terra Lasho, Animesh Pardanani
JOURNAL OF CLINICAL ONCOLOGY
(2011)
Letter
Oncology
A. Tefferi, A. Pardanani, N. Gangat, K. H. Begna, C. A. Hanson, D. L. Van Dyke, D. Caramazza, A. M. Vannucchi, E. Morra, M. Cazzola, A. Pereira, F. Cervantes, F. Passamonti
Letter
Oncology
M. Maffioli, A. Genoni, D. Caramazza, B. Mora, A. Bussini, M. Merli, T. Giorgino, R. Casalone, F. Passamonti
Article
Oncology
A. Tefferi, T. L. Lasho, C. M. Finke, R. A. Knudson, R. Ketterling, C. H. Hanson, M. Maffioli, D. Caramazza, F. Passamonti, A. Pardanani
Article
Hematology
Francesco Dentali, Walter Ageno, Elisa Rumi, Ilaria Casetti, Daniela Poli, Umberto Scoditti, Margherita Maffioli, Matteo Nicola Dario di Minno, Domenica Caramazza, Daniela Pietra, Valerio De Stefano, Francesco Passamonti
THROMBOSIS RESEARCH
(2014)
Letter
Medicine, General & Internal
Francesco Passamonti, Domenica Caramazza, Margherita Maffioli
NEW ENGLAND JOURNAL OF MEDICINE
(2014)
Review
Hematology
Michele Merli, Andrea Ferrario, Claudia Basilico, Margherita Maffioli, Domenica Caramazza, Lorena Appio, Luca Arcaini, Francesco Passamonti
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2013)
Article
Oncology
Francesco Passamonti, Margherita Maffioli, Domenica Caramazza, Mario Cazzola